WO2025049941 - ATTENUATED VACCINIA VIRUS VACCINES FOR MONKEYPOX
National phase entry is expected:
Publication Number
WO/2025/049941
Publication Date
06.03.2025
International Application No.
PCT/US2024/044723
International Filing Date
30.08.2024
Title **
[English]
ATTENUATED VACCINIA VIRUS VACCINES FOR MONKEYPOX
[French]
VACCINS ATTÉNUÉS CONTRE LE VIRUS DE LA VACCINE CONTRE L'ORTHOPOXVIROSE SIMIENNE
Applicants **
ARIZONA BOARD OF REGENTS on behalf of ARIZONA STATE UNIVERSITY
Inventors
KIBLER, Karen
JACOBS, Bertram
Priority Data
63/535,964
31.08.2023
US
63/536,538
05.09.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2215 | |
| EPO | Filing, Examination, Granting | 12606 | |
| Japan | Filing, Examination, Granting | 2223 | |
| South Korea | Filing, Examination, Granting | 2284 | |
| USA | Filing, Examination, Granting | 4910 |
Total:
24,238
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This disclosure provides compositions and methods for treating and/or preventing monkeypox infection and/or symptoms post-infection, the method including administering a composition including at least one attenuated vaccinia virus, the at least one attenuated vaccinia virus including a modification to the coding sequence of E3L.[French]
La présente divulgation concerne des compositions et des méthodes de traitement et/ou de prévention d'une infection à l'orthopoxvirose simienne et/ou de symptômes post-infection, la méthode comprenant l'administration d'une composition comprenant au moins un virus de la vaccine atténué, le ou les virus de la vaccine atténués comprenant une modification de la séquence de codage de E3L.